Durability Results of Treatment with Brentuximab Vedotin in Combination with Nivolumab in Patient with Relapsed or Refractory Hodgkin Lymphoma
Hodgkin’s lymphoma (HL) is a disease that represents approximately 10% of lymphomas with bimodal age distribution. It is curable in approximately 75 percent of patients worldwide. ABVD regimen (doxorubicin, bleomycin, vinblastine, and dacarbazine) was originally developed for patients with disease r...
Main Authors: | Minhas, Ahmed, Manthri, Sukesh, Masood, Sara, Spradling, Elnora, Jaishankar, Devapiran |
---|---|
Published: |
Digital Commons @ East Tennessee State University
2020
|
Subjects: | |
Online Access: | https://dc.etsu.edu/asrf/2020/presentations/24 |
Similar Items
-
Pharmacoeconomic analysis of therapy with brentuximab vedotin, nivolumab and pembrolizumab in patients with relapsed Hodgkin’s lymphoma
by: N. A. Avxentyev, et al.
Published: (2020-12-01) -
Brentuximab vedotin in the treatment of relapsed and refractory forms of Hodgkin lymphoma
by: E A Demina
Published: (2016-06-01) -
Brentuximab Vedotin: New Possibilities for Treatment of Relapses and Refractory Hodgkin’s Lymphomas
by: EA Demina
Published: (2015-10-01) -
The Use of Brentuximab Vedotin in Relapsed/Refractory Hodgkin’s Lymphoma in the Kransnodar Region
by: OD Serdyuk, et al.
Published: (2018-01-01) -
Brentuximab Vedotin for Treatment of Non-Hodgkin Lymphomas: A Systematic Review
by: Berger, Garrett, et al.
Published: (2017)